Aberdeen Group
RPRX icon

Aberdeen Group’s Royalty Pharma RPRX Stock Holding History

Aberdeen Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4M Buy
578,201
+4,455
+0.8% +$232K 0.05% 314
2026
Q1 		$27.5M Sell
573,746
-87,670
-13% -$3.84M 0.04% 327
2025
Q4 		$25.6M Buy
661,416
+98,191
+17% +$3.74M 0.04% 347
2025
Q3 		$19.7M Buy
563,225
+334,479
+146% +$12.1M 0.03% 436
2025
Q2 		$8.21M Buy
228,746
+14,886
+7% +$493K 0.01% 641
2025
Q1 		$6.59M Buy
213,860
+124,193
+139% +$3.94M 0.01% 648
2024
Q4 		$2.28M Sell
89,667
-14,685
-14% -$389K ﹤0.01% 751
2024
Q3 		$2.93M Sell
104,352
-1,083,657
-91% -$30M 0.01% 732
2024
Q2 		$31.3M Sell
1,188,009
-110,391
-9% -$3.06M 0.06% 284
2024
Q1 		$39.4M Buy
1,298,400
+41,032
+3% +$1.21M 0.08% 249
2023
Q4 		$35.3M Sell
1,257,368
-2,448,301
-66% -$67.3M 0.08% 265
2023
Q3 		$101M Sell
3,705,669
-169,484
-4% -$5.03M 0.26% 91
2023
Q2 		$119M Sell
3,875,153
-103,262
-3% -$3.5M 0.28% 86
2023
Q1 		$143M Buy
3,978,415
+460,938
+13% +$17.1M 0.36% 63
2022
Q4 		$139M Buy
3,517,477
+83,405
+2% +$3.48M 0.38% 63
2022
Q3 		$138M Sell
3,434,072
-132,822
-4% -$5.67M 0.41% 56
2022
Q2 		$150M Buy
3,566,894
+1,327,764
+59% +$54.4M 0.47% 51
2022
Q1 		$87.5M Sell
2,239,130
-46,769
-2% -$1.84M 0.22% 101
2021
Q4 		$91.1M Buy
2,285,899
+484,754
+27% +$18.8M 0.2% 117
2021
Q3 		$65.1M Sell
1,801,145
-82,866
-4% -$3.22M 0.15% 145
2021
Q2 		$77.2M Buy
1,884,011
+1,855,388
+6,482% +$78.9M 0.17% 122
2021
Q1 		$1.25M Buy
28,623
+18,420
+181% +$873K ﹤0.01% 832
2020
Q4 		$510K Buy
+10,203
New +$433K ﹤0.01% 882

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group's RPRX Position: Q2 2026 in Review

Aberdeen Group increased its Royalty Pharma (RPRX) stake by 0.78% in Q2 2026, buying an estimated $232K and bringing the position to 578,201 shares worth $32.4M. The position accounts for 0.05% of the portfolio, ranked #314.

Aberdeen Group first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $150M in Q2 2022. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Aberdeen Group held 578,201 shares of Royalty Pharma worth $32.4M as of Q2 2026.
  • Aberdeen Group bought 4,455 Royalty Pharma shares in Q2 2026, an estimated $232K.
  • Royalty Pharma made up 0.05% of Aberdeen Group's portfolio in Q2 2026, its #314 holding.
  • Aberdeen Group first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • Aberdeen Group's Royalty Pharma position peaked at $150M in Q2 2022.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.